|Diversion Control Program (DEA)||Preventing Diversion||Not specified||February 28, 2020||DEA-DC-13||General||
The document discusses ways for practitioners to be aware of signs that patients are trying to access drugs for diversion, such as giving vague symptoms, exaggerating pain, or avoiding tests and accessing medical history. The document also discusses ways for practitioners to avoid giving out prescriptions that could lead to diversion. Practitioners must assure they conduct medical examinations and tests while also looking out for signs of abuse when dealing with patients.
|Diversion Control Program (DEA)||Preventing the Retail Diversion of Pseudoephedrine||Not specified||February 28, 2020||DEA-DC-4||General||
Summary of the Combat Methamphetamine Epidemic Act of 2005 (CMEA). Preventing the Retail Diversion of Pseudoephedrine, including CMEA requirements, methamphetamine background information, and DEA’s goals in combating the methamphetamine epidemic.
|Diversion Control Program (DEA)||Clarification of Title 21 CFR 1301.90 - Employee Screening - Non-Practitioners||Not specified||February 28, 2020||DEA-DC-6||Controlled Substance Security||
This document identified a DEA regulation that may create unintended consequences for a formerly incarcerated individual that is attempting to successfully reenter society. Specifically, 21 CFR 1301.90 has been identified as such because this regulation sets forth specific questions in order for a non-practitioner to comprehensively screen employees.
|Diversion Control Program (DEA)||Questions and Answers for Prescribing Practitioners (EPCS)||Not specified||February 28, 2020||DEA-DC-9||Controlled Substance Prescriptions||
All records for prescribing of an FDA-approved narcotic for the treatment of opioid addiction need to be kept in accordance with 21 CFR 1304.03(c), 21 CFR 1304.21(b).